Skip to main content
SpringerLink
Log in
Book cover

Acute Ischemic Stroke pp 27–34Cite as

Pathophysiology of Moyamoya Disease

  • Chapter
  • First Online:

  • 2143 Accesses

Abstract

Moyamoya disease is a chronic progressive steno-occlusive disease of the distal internal carotid artery or proximal anterior cerebral artery and the middle cerebral artery with abnormal moyamoya collateral vessels without associated diseases. The disease has been increasingly reported due to the technological advances of diagnostic radiology and an increase of health check-up. The studies regarding the incidence, prevalence, natural clinical course, disease progression, and surgical treatment outcomes have been increasingly reported. Nevertheless, the precise mechanism of the disease still remains to be investigated further. In addition, heterogeneity of the ethnicity, different age at presentation, different degrees of hemodynamic compromise, surgical techniques such as direct bypass or indirect bypass surgery, and relative small sample size could lead to controversial results. This chapter provides insights into the pathophysiology of the disease including histopathological features, genetics, Ring finger protein 213, microRNAs, molecular biomarkers, vascular progenitor cells, proteomics, metabolomics, and associated autoimmune diseases.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Suzuki J, Takaku A. Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20:288–99.

    Article  CAS  PubMed  Google Scholar 

  2. Kuriyama S, Kusaka Y, Fujimura M, et al. Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke. 2008;39:42–7.

    Article  PubMed  Google Scholar 

  3. Kim T, Lee H, Bang JS, et al. Epidemiology of moyamoya disease in Korea: based on National Health Insurance Service Data. J Korean Neurosurg Soc. 2015;57:390–5.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009;360:1226–37.

    Article  CAS  PubMed  Google Scholar 

  5. Kuroda S, Ishikawa T, Houkin K, et al. Incidence and clinical features of disease progression in adult moyamoya disease. Stroke. 2005;36:2148–53.

    Article  PubMed  Google Scholar 

  6. Smith ER, Scott RM. Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus. 2008;24:E17.

    Article  PubMed  Google Scholar 

  7. Lee SC, Jeon JS, Kim JE, et al. Contralateral progression and its risk factor in surgically treated unilateral adult moyamoya disease with a review of pertinent literature. Acta Neurochir. 2014;156:103–11.

    Article  PubMed  Google Scholar 

  8. Kuroda S, Hashimoto N, Yoshimoto T, et al. Research Committee on Moyamoya Disease in J. Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease: results of multicenter survey in Japan. Stroke. 2007;38:1430–5.

    Article  PubMed  Google Scholar 

  9. Fukui M, Kono S, Sueishi K, et al. Moyamoya disease. Neuropathology. 2000;20(Suppl):S61–4.

    Article  PubMed  Google Scholar 

  10. Bersano A, Guey S, Bedini G, et al. Research progresses in understanding the pathophysiology of moyamoya disease. Cerebrovas Dis. 2016;41:105–18.

    Article  Google Scholar 

  11. Bang OY, Fujimura M, Kim SK. The pathophysiology of moyamoya disease: an update. J Stroke. 2016;18:12–20.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. 2008;7:1056–66.

    Article  PubMed  Google Scholar 

  13. Kaku Y, Morioka M, Ohmori Y, et al. Outer-diameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3D constructive interference in steady-state MR image: is arterial constrictive remodeling a major pathogenesis? Acta Neurochir. 2012;154:2151–7.

    Article  PubMed  Google Scholar 

  14. Aoyagi M, Ogami K, Matsushima Y, et al. Human leukocyte antigen in patients with moyamoya disease. Stroke. 1995;26:415–7.

    Article  CAS  PubMed  Google Scholar 

  15. Han H, Pyo CW, Yoo DS, et al. Associations of Moyamoya patients with HLA class I and class II alleles in the Korean population. J Korean Med Sci. 2003;18:876–80.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hong SH, Wang KC, Kim SK, et al. Association of HLA-DR and -DQ genes with familial moyamoya disease in Koreans. J Korean Neurosurg Soc. 2009;46:558–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Inoue TK, Ikezaki K, Sasazuki T, et al. DNA typing of HLA in the patients with moyamoya disease. Jpn J Hum Genet. 1997;42:507–15.

    Article  CAS  PubMed  Google Scholar 

  18. Kang HS, Kim SK, Cho BK, et al. Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease. Neurosurgery. 2006;58:1074–80.

    Article  PubMed  Google Scholar 

  19. Paez MT, Yamamoto T. Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease. Neurosurgery. 2007;60:E582.

    Article  PubMed  Google Scholar 

  20. Andreone V, Scala S, Tucci C, et al. Single nucleotide polymorphisms of tissue inhibitors of metalloproteinase genes in familial moyamoya disease. Neurosurgery. 2008;62:E1384.

    Article  Google Scholar 

  21. Ikeda H, Sasaki T, Yoshimoto T, et al. Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet. 1999;64:533–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Inoue TK, Ikezaki K, Sasazuki T, et al. Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol. 2000;15:179–82.

    Article  CAS  PubMed  Google Scholar 

  23. Sakurai K, Horiuchi Y, Ikeda H, et al. A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet. 2004;49:278–81.

    Article  CAS  PubMed  Google Scholar 

  24. Yamauchi T, Tada M, Houkin K, et al. Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke. 2000;31:930–5.

    Article  CAS  PubMed  Google Scholar 

  25. Kamada F, Aoki Y, Narisawa A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011;56:34–40.

    Article  CAS  PubMed  Google Scholar 

  26. Liu W, Morito D, Takashima S, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS ONE. 2011;6:e22542.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Miyatake S, Miyake N, Touho H, et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology. 2012;78:803–10.

    Article  CAS  PubMed  Google Scholar 

  28. Wu Z, Jiang H, Zhang L, et al. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS ONE. 2012;7:e48179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kim EH, Yum MS, Ra YS, et al. Importance of RNF213 polymorphism on clinical features and long-term outcome in moyamoya disease. J Neurosurg. 2015;124:1221–7.

    Article  PubMed  Google Scholar 

  30. Cecchi AC, Guo D, Ren Z, et al. RNF213 rare variants in an ethnically diverse population with Moyamoya disease. Stroke. 2014;45:3200–7.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Wang X, Zhang Z, Liu W, et al. Impacts and interactions of PDGFRB, MMP-3, TIMP-2, and RNF213 polymorphisms on the risk of Moyamoya disease in Han Chinese human subjects. Gene. 2013;526:437–42.

    Article  CAS  PubMed  Google Scholar 

  32. Sonobe S, Fujimura M, Niizuma K, et al. Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213: a susceptibility gene for moyamoya disease. Brain Res. 2014;1552:64–71.

    Article  CAS  PubMed  Google Scholar 

  33. Kanoke A, Fujimura M, Niizuma K et al. Temporal profile of the vascular anatomy evaluated by 9.4-tesla magnetic resonance angiography and histological analysis in mice with the R4859K mutation of RNF213, the susceptibility gene for moyamoya disease. Brain Res. 2015;1624:497–505.

    Google Scholar 

  34. Dai D, Lu Q, Huang Q, et al. Serum miRNA signature in Moyamoya disease. PLoS ONE. 2014;9:e102382.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Liu P, Zhao H, Wang R, et al. MicroRNA-424 protects against focal cerebral ischemia and reperfusion injury in mice by suppressing oxidative stress. Stroke. 2015;46:513–9.

    Article  CAS  PubMed  Google Scholar 

  36. Park YS, Jeon YJ, Lee BE, et al. Association of the miR-146aC>G, miR-196a2C>T, and miR-499A>G polymorphisms with moyamoya disease in the Korean population. Neurosci Lett. 2012;521:71–5.

    Article  CAS  PubMed  Google Scholar 

  37. Takahashi A, Sawamura Y, Houkin K, et al. The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci Lett. 1993;160:214–6.

    Article  CAS  PubMed  Google Scholar 

  38. Houkin K, Abe H, Yoshimoto T, et al. Is “unilateral” moyamoya disease different from moyamoya disease. J Neurosurg. 1996;85:772–6.

    Article  CAS  PubMed  Google Scholar 

  39. Yoshimoto T, Houkin K, Takahashi A, et al. Angiogenic factors in moyamoya disease. Stroke. 1996;27:2160–5.

    Article  CAS  PubMed  Google Scholar 

  40. Malek AM, Connors S, Robertson RL, et al. Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders. Pediatr Neurosurg. 1997;27:182–9.

    Article  CAS  PubMed  Google Scholar 

  41. Hojo M, Hoshimaru M, Miyamoto S, et al. Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg. 1998;89:623–9.

    Article  CAS  PubMed  Google Scholar 

  42. Soriano SG, Cowan DB, Proctor MR, et al. Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya syndrome. Neurosurgery. 2002;50:544–9.

    PubMed  Google Scholar 

  43. Kim SK, Yoo JI, Cho BK, et al. Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease. Stroke. 2003;34:2835–41.

    Article  CAS  PubMed  Google Scholar 

  44. Amano T, Inoha S, Wu CM, et al. Serum alpha1-antitrypsin level and phenotype associated with familial moyamoya disease. Childs Nerv Syst. 2003;19:655–8.

    Article  PubMed  Google Scholar 

  45. Nanba R, Kuroda S, Ishikawa T, et al. Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke. 2004;35:2837–42.

    Article  CAS  PubMed  Google Scholar 

  46. Kang HS, Kim JH, Phi JH, et al. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry. 2010;81:673–8.

    Article  PubMed  Google Scholar 

  47. Bernard TJ, Fenton LZ, Apkon SD, et al. Biomarkers of hypercoagulability and inflammation in childhood-onset arterial ischemic stroke. J Pediatr. 2010;156:651–6.

    Article  CAS  PubMed  Google Scholar 

  48. Jeon JS, Ahn JH, Moon YJ, et al. Expression of cellular retinoic acid-binding protein-I (CRABP-I) in the cerebrospinal fluid of adult onset moyamoya disease and its association with clinical presentation and postoperative haemodynamic change. J Neurol Neurosurg Psychiatry. 2014;85:726–31.

    Article  PubMed  Google Scholar 

  49. Smith ER. Moyamoya biomarkers. J Korean Neurosurg Soc. 2015;57:415–21.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Johnson C, Galis ZS. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol. 2004;24:54–60.

    Article  CAS  PubMed  Google Scholar 

  51. Demicheva E, Hecker M, Korff T. Stretch-induced activation of the transcription factor activator protein-1 controls monocyte chemoattractant protein-1 expression during arteriogenesis. Circ Res. 2008;103:477–84.

    Article  CAS  PubMed  Google Scholar 

  52. Rafat N, Beck G, Pena-Tapia PG, et al. Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Stroke. 2009;40:432–8.

    Article  CAS  PubMed  Google Scholar 

  53. Sugiyama T, Kuroda S, Nakayama N, et al. Bone marrow-derived endothelial progenitor cells participate in the initiation of moyamoya disease. Neurol Med Chir (Tokyo). 2011;51:767–73.

    Article  Google Scholar 

  54. Jung KH, Chu K, Lee ST, et al. Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease. J Cereb Blood Flow Metab. 2008;28:1795–180.

    Article  CAS  PubMed  Google Scholar 

  55. Kim JH, Jung JH, Phi JH, et al. Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease. J Neurosci Res. 2010;88:510–8.

    CAS  PubMed  Google Scholar 

  56. Lee JY, Moon YJ, Lee HO, et al. Deregulation of retinaldehyde dehydrogenase 2 leads to defective angiogenic function of endothelial colony-forming cells in pediatric Moyamoya Disease. Arterioscler Thromb Vasc Biol. 2015;35:1670–7.

    Article  CAS  PubMed  Google Scholar 

  57. Yoshihara T, Taguchi A, Matsuyama T, et al. Increase in circulating CD34-positive cells in patients with angiographic evidence of moyamoya-like vessels. J Cereb Blood Flow Metab. 2008;28:1086–9.

    Article  CAS  PubMed  Google Scholar 

  58. Ni G, Liu W, Huang X, et al. Increased levels of circulating SDF-1alpha and CD34+ CXCR4+ cells in patients with moyamoya disease. Eur J Neurol. 2011;18:1304–9.

    Article  CAS  PubMed  Google Scholar 

  59. Kang HS, Moon YJ, Kim YY, et al. Smooth-muscle progenitor cells isolated from patients with moyamoya disease: novel experimental cell model. J Neurosurg. 2014;120:415–25.

    Article  CAS  PubMed  Google Scholar 

  60. Kang HS, Wang KC, Kim SK. Circulating vascular progenitor cells in moyamoya disease. J Korean Neurosurg Soc. 2015;57:428–31.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Maruwaka M, Yoshikawa K, Okamoto S, et al. Biomarker research for moyamoya disease in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. J Stroke Cerebrovasc Dis. 2015;24:104–11.

    Article  PubMed  Google Scholar 

  62. Jeon JP, Yun T, Jin X, et al. 1H-NMR-based metabolomic analysis of cerebrospinal fluid from adult bilateral moyamoya disease: comparison with unilateral moyamoya disease and atherosclerotic stenosis. Medicine. 2015;94:e629.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Wurtz P, Raiko JR, Magnussen CG, et al. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur Heart J. 2012;33:2307–16.

    Article  PubMed  Google Scholar 

  64. Tendler BE, Shoukri K, Malchoff C, et al. Concurrence of Graves’ disease and dysplastic cerebral blood vessels of the moyamoya variety. Thyroid. 1997;7:625–9.

    Article  CAS  PubMed  Google Scholar 

  65. Liu JS, Juo SH, Chen WH, et al. A case of graves’ diseases associated with intracranial moyamoya vessels and tubular stenosis of extracranial internal carotid arteries. J Formos Med Assoc. 1994;93:806–9.

    CAS  PubMed  Google Scholar 

  66. Kim SJ, Heo KG, Shin HY, et al. Association of thyroid autoantibodies with moyamoya-type cerebrovascular disease: a prospective study. Stroke. 2010;41:173–6.

    Article  PubMed  Google Scholar 

  67. Chen JB, Liu Y, Zhou LX, et al. Increased prevalence of autoimmune disease in patients with unilateral compared with bilateral moyamoya disease. J Neurosurg. 2016;124:1215–20.

    Article  PubMed  Google Scholar 

  68. Kim JE, Jeon JS. An update on the diagnosis and treatment of adult Moyamoya disease taking into consideration controversial issues. Neurol Res. 2014;36:407–16.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Hallym University College of Medicine, Chuncheon, South Korea

    Jin Pyeong Jeon MD

  2. Department of Neurosurgery, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, South Korea

    Jeong Eun Kim MD, PhD

Authors
  1. Jin Pyeong Jeon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeong Eun Kim MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeong Eun Kim MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Neurosurgery, Kyungpook National University Hospital, Daegu, Korea (Republic of)

    Jaechan Park

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Jeon, J.P., Kim, J.E. (2017). Pathophysiology of Moyamoya Disease. In: Park, J. (eds) Acute Ischemic Stroke. Springer, Singapore. https://doi.org/10.1007/978-981-10-0965-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-0965-5_2

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-0964-8

  • Online ISBN: 978-981-10-0965-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation